Completion of enrolment and treatment in the phase 1 study of mtx110 in the treatment of children with newly diagnosed diffuse midline gliomas (dmgs)

10 july 2023 biodexa ltd (“biodexa” or the “company”) completion of enrolment and treatment in the phase 1 study of mtx110 in the treatment of children with newly diagnosed diffuse midline gliomas (dmgs) biodexa ltd (a wholly owned subsidiary of biodexa pharmaceuticals plc, nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, is pleased to announce completion of enrolment and treatment of nine paediatric patients into the ongoing investigator-sponsored phase i study of mtx-110 in newly diagnosed dmgs (nct 04264143). all of the  patients (age range 4-17 years) were enrolled at the columbia university irving medical centre and received radiation therapy as per the institution's standard of care.
BDRX Ratings Summary
BDRX Quant Ranking